cholecalciferol and Chronic-Pain

cholecalciferol has been researched along with Chronic-Pain* in 2 studies

Other Studies

2 other study(ies) available for cholecalciferol and Chronic-Pain

Article	Year
Supplementation of vitamin D and reduction of analgesic requirements in institutionalized elderly with chronic musuloskeletal pain. Medicina clinica, 2017, 07-21, Volume: 149, Issue:2 Topics: Aged; Aged, 80 and over; Analgesics; Cholecalciferol; Chronic Pain; Dietary Supplements; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Musculoskeletal Pain; Retrospective Studies; Treatment Outcome; Vitamin D Deficiency; Vitamins	2017
Efficacy of vitamin D replacement therapy on patients with chronic nonspecific widespread musculoskeletal pain with vitamin D deficiency. International journal of rheumatic diseases, 2016, Volume: 19, Issue:12 The objective of this study is the evaluation of the effect of vitamin D replacement treatment on musculoskeletal symptoms and quality of life in patients with chronic widespread musculoskeletal pain (CWP) including fibromyalgia (FM) and vitamin D deficiency.. Patients with nonspecific CWP and vitamin D deficiency (25-OH D3 < 25 ng/mL) were included into the study. Replacement treatments of 50 000 IU/week oral vitamin D3 for 3 months were given to the patients. Patients were assessed pre- and post-treatment in terms of serum levels of Ca, P, alkaline phosphatase, 25-OH D3, severity of pain (visual analogue scale [VAS]-pain), severity of asthenia (VAS-asthenia), Beck Depression Inventory (BDI), quality of life scale (Short Form [SF]-36), tender point count (TPC), severity of waking unrefreshed, headache, tenderness on tibia, meeting the criteria of FM, and level of patient satisfaction.. Fifty-eight patients with a mean age of 36.9 ± 9.2 years were included into the study. 25-OH D3 levels of patients elevated from 10.6 ± 5.1 ng/mL to 46.5 ± 24.0 ng/mL after replacement treatment (P < 0.001). Marked decrease in VAS-pain, VAS-asthenia, severity of waking unrefreshed, TPC, and BDI and an evident increase in subgroups of SF-36 were established in patients after treatment (P < 0.001). The number of FM+ patients was 30 (52%) before treatment and regressed to 20 (34%) after treatment (P = 0.013); 85% of patients stated satisfaction with the treatment.. Vitamin D replacement treatment in patients with nonspecific CWP has provided improvements in musculoskeletal symptoms, level of depression and quality of life of patients. Patients with CWP should be investigated for vitamin D deficiency. Topics: Adult; Alkaline Phosphatase; Calcifediol; Calcium; Cholecalciferol; Chronic Pain; Depression; Dietary Supplements; Female; Fibromyalgia; Humans; Male; Middle Aged; Musculoskeletal Pain; Pain Measurement; Phosphates; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vitamin D Deficiency	2016

Article

Year

Supplementation of vitamin D and reduction of analgesic requirements in institutionalized elderly with chronic musuloskeletal pain.

Medicina clinica, 2017, 07-21, Volume: 149, Issue:2

Topics: Aged; Aged, 80 and over; Analgesics; Cholecalciferol; Chronic Pain; Dietary Supplements; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Musculoskeletal Pain; Retrospective Studies; Treatment Outcome; Vitamin D Deficiency; Vitamins

2017

Efficacy of vitamin D replacement therapy on patients with chronic nonspecific widespread musculoskeletal pain with vitamin D deficiency.

International journal of rheumatic diseases, 2016, Volume: 19, Issue:12

The objective of this study is the evaluation of the effect of vitamin D replacement treatment on musculoskeletal symptoms and quality of life in patients with chronic widespread musculoskeletal pain (CWP) including fibromyalgia (FM) and vitamin D deficiency.. Patients with nonspecific CWP and vitamin D deficiency (25-OH D3 < 25 ng/mL) were included into the study. Replacement treatments of 50 000 IU/week oral vitamin D3 for 3 months were given to the patients. Patients were assessed pre- and post-treatment in terms of serum levels of Ca, P, alkaline phosphatase, 25-OH D3, severity of pain (visual analogue scale [VAS]-pain), severity of asthenia (VAS-asthenia), Beck Depression Inventory (BDI), quality of life scale (Short Form [SF]-36), tender point count (TPC), severity of waking unrefreshed, headache, tenderness on tibia, meeting the criteria of FM, and level of patient satisfaction.. Fifty-eight patients with a mean age of 36.9 ± 9.2 years were included into the study. 25-OH D3 levels of patients elevated from 10.6 ± 5.1 ng/mL to 46.5 ± 24.0 ng/mL after replacement treatment (P < 0.001). Marked decrease in VAS-pain, VAS-asthenia, severity of waking unrefreshed, TPC, and BDI and an evident increase in subgroups of SF-36 were established in patients after treatment (P < 0.001). The number of FM+ patients was 30 (52%) before treatment and regressed to 20 (34%) after treatment (P = 0.013); 85% of patients stated satisfaction with the treatment.. Vitamin D replacement treatment in patients with nonspecific CWP has provided improvements in musculoskeletal symptoms, level of depression and quality of life of patients. Patients with CWP should be investigated for vitamin D deficiency.

Topics: Adult; Alkaline Phosphatase; Calcifediol; Calcium; Cholecalciferol; Chronic Pain; Depression; Dietary Supplements; Female; Fibromyalgia; Humans; Male; Middle Aged; Musculoskeletal Pain; Pain Measurement; Phosphates; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vitamin D Deficiency

2016